HER2 Overexpression/Amplification and Trastuzumab Treatment in Advanced Ovarian Cancer: A GINECO Phase II Study

This publication has 16 references indexed in Scilit:

• HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
  PLOS ONE, 2007
• Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma
  Journal of Molecular Medicine, 2006
• Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group
  Journal of Clinical Oncology, 2003
• Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
  New England Journal of Medicine, 2001
• Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]
  JNCI: Journal of the National Cancer Institute, 2000
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI: Journal of the National Cancer Institute, 2000
• Overexpression of the Oncogene c-erbB-2 (HER2/neu) and Response to Chemotherapy in Patients with Ovarian Cancer
  International Journal of Gynecological Pathology, 1998
• Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy
  Cancer, 1995
• Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
  Journal of Clinical Oncology, 1991
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogene
  Science, 1987